Clinical trials: Lenalidomide
Prostate Cancer
Study of 2 Different Doses of Revlimid in Biochemically Relapse Prostate Cancer
The primary objectives of the study are: To evaluate feasibility, safety and tolerance of 6 months administration of Revlimid at 5mg/day and 25mg/day, given orally in subjects with prostate cancer with evidence of biochemical…
- Trial name
- NCT00348595
- Testing
- Revlimid
- Where
- United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins